Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 11, 2014, Pages 3006-3010

  Barber, Katie E ^a   Werth, Brian J ^a   Ireland, Cortney E ^a   Stone, Nicole E ^a   Nonejuie, Poochit ^b   Sakoulas, George ^c   Pogliano, Joseph ^b   Rybak, Michael J ^a,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hVISA; MRSA; Seesaw effect; VISA

Indexed keywords

CEFTOBIPROLE; DAPTOMYCIN; GENTAMICIN; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BROTH DILUTION; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; DRUG POTENTIATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PHENOTYPE; PROCEDURES; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; STAPHYLOCOCCUS AUREUS;

EID: 84908272497     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku236     Document Type: Article

References (20)

1. Sievert DM, Ricks P, Edwards JR et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34: 1-14.
2. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
3. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-71.
4. Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC creep'): implications for therapy. F1000 Med Rep 2012; 4: 4.
5. Cui L, Tominaga E, Neoh HM et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-82.
6. Sakoulas G, Alder J, Thauvin-Eliopoulos C et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50: 1581-5.
7. Chong YP, Park SJ, Kim HS et al. In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC. Diagn Microbiol Infect Dis 2012; 73: 264-6.
8. Saravolatz LD, Pawlak J, Johnson LB et al. In vitro activity of ceftobiprole against methicillin-resistant Staphylococcus aureus (MRSA), vancomycinintermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int J Antimicrob Agents 2010; 36: 478-80.
9. Dhand A, Bayer AS, Pogliano J et al. Use of antistaphylococcal b-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53: 158-63.
10. Mwangi MM,Wu SW, Zhou Y et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 104: 9451-6.
11. Ortwine JK,Werth BJ, Sakoulas G et al. Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the 'seesaw effect': taking advantage of the back door left open? Drug Resist Updat 2013; 16: 73-9.
12. Jones T, Yeaman MR, Sakoulas G et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008; 52: 269-78.
13. Werth BJ, Sakoulas G, Rose WE et al. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycinnonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013; 57: 66-73.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
15. Werth BJ, Vidaillac C, Murray KP et al. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycinintermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother 2013; 57: 2376-9.
16. Vidaillac C, Parra-Ruiz J, Rybak MJ. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin. Diagn Microbiol Infect Dis 2011; 71: 470-3.
17. Mishra NN, Bayer AS, Moise PA et al. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillinresistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis 2012; 206: 1160-7.
18. Sakoulas G, Eliopoulos GM, Fowler VG Jr et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005; 49: 2687-92.
19. Mishra NN, Yang SJ, Chen L et al. Emergence of daptomycin resistance in daptomycin-naive rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PloS One 2013; 8: e71151.
20. Sakoulas G, Okumura CY, Thienphrapa W et al. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med 2014; 92: 139-49.